ANA screening: An old test with new recommendations

Pier Luigi Meroni, Peter H. Schur

Research output: Contribution to journalArticlepeer-review

Abstract

The impact of autoimmune diseases is growing from both a clinical and a laboratory point of view. Diagnostic assays are now being transferred from dedicated specialised laboratories into high-throughput service laboratories. The increasing number of available methods has raised the variability among the laboratories, making their reproducibility a critical problem. On the other hand, reliable tests are needed for early diagnosis and prompt treatment, and the cost of repeated confirmatory tests should be reduced and unnecessary further investigations avoided. New methodologies, particularly for antinuclear antibodies (ANAs), have been applied to autoantibody detection in order to screen and process larger volumes of clinical specimens more quickly and at less cost than the traditional methods. However, because of the lack of their sensitivity to detect all ANAs and standardisation, inaccuracies (including false positives and negatives) in the results have been reported. A committee of the American College of Rheumatology was formed to address this issue. Specific recommendations have been suggested that represent a realistic first step in the standardisation of diagnostic tests for autoimmune diseases.

Original languageEnglish
Pages (from-to)1420-1422
Number of pages3
JournalAnnals of the Rheumatic Diseases
Volume69
Issue number8
DOIs
Publication statusPublished - Aug 2010

ASJC Scopus subject areas

  • Rheumatology
  • Immunology
  • Biochemistry, Genetics and Molecular Biology(all)
  • Immunology and Allergy

Fingerprint

Dive into the research topics of 'ANA screening: An old test with new recommendations'. Together they form a unique fingerprint.

Cite this